18,065 Abeona shares flagged for Rule 144 sale

Abeona Therapeutics shareholder filed a notice of proposed sale under Rule 144 for 18,065 shares of common stock through Stifel Nicolaus & Company on 02/02/2026 on Nasdaq.

Rhea-AI Filing Summary

Abeona Therapeutics shareholder filed a notice of proposed sale under Rule 144 for 18,065 shares of common stock through Stifel Nicolaus & Company on 02/02/2026 on Nasdaq. The filing lists an aggregate market value of $91,962.00 for these shares and notes that 54,191,361 shares of common stock were outstanding.

The seller acquired 36,101 shares of common stock on 01/31/2026 via restricted stock units granted as equity compensation from the issuer, with payment also dated 01/31/2026. The form states the signer represents they are not aware of undisclosed material adverse information about Abeona’s current or prospective operations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for Abeona Therapeutics (ABEO) disclose?

The filing discloses a planned Rule 144 sale of 18,065 Abeona Therapeutics common shares with an aggregate market value of $91,962.00. It also notes that 54,191,361 shares of common stock were outstanding when the notice was prepared.

How many Abeona Therapeutics (ABEO) shares are planned to be sold and through which broker?

The notice covers a planned sale of 18,065 shares of Abeona Therapeutics common stock. The shares are to be sold through Stifel Nicolaus & Company Inc., using its office at 501 N Broadway, St. Louis, Missouri, with trading to occur on Nasdaq.

When is the planned Rule 144 sale for Abeona Therapeutics (ABEO) shares scheduled?

The approximate date of sale for the 18,065 Abeona Therapeutics common shares is listed as 02/02/2026. This date reflects when the holder expects to begin sales, subject to market conditions and the requirements of SEC Rule 144.

How were the Abeona Therapeutics (ABEO) shares in this Form 144 acquired?

The filing states the securities were acquired as restricted stock units from the issuer on 01/31/2026. It lists 36,101 shares acquired through equity compensation, with the acquisition date and payment date both shown as 01/31/2026.

What does the Form 144 say about Abeona Therapeutics (ABEO) insider information?

The signer represents that they do not know any material adverse information about Abeona’s current or prospective operations that has not been publicly disclosed. This representation is a standard part of the Rule 144 notice language included in the form.

How many Abeona Therapeutics (ABEO) shares were outstanding at the time of the Form 144 notice?

The document reports that 54,191,361 shares of Abeona Therapeutics common stock were outstanding. This figure provides context for the planned sale of 18,065 shares under Rule 144, showing the relative size of the proposed transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 04:39 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001825216
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ABEONA THERAPEUTICS INC.
SEC File Number	001-15771
Address of Issuer	6555 CARNEGIE AVE, 4TH FLOOR CLEVELAND OHIO 44103
Phone	646-813-4701
Name of Person for Whose Account the Securities are To Be Sold	Alland Leila
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	18065	91962.00	54191361	02/02/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/31/2026	Restricted Stock Units	Issuer			36101	01/31/2026	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The shares were sold to cover tax obligations pursuant to an RSA vesting event.
Date of Notice	02/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Luca Lotito, as a duly authorized representative of STIFEL, as attorney-in-fact for Leila Alland
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)